Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA

Vaccine

Volumn 18, Issue 5-6, 1999, Pages 392-397

  Wyatt, Linda S ^a   Whitehead, Stephen S ^a   Venanzi, Katherine A ^a   Murphy, Brian R ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

MVA strain; Respiratory syncytial virus; Vaccinia virus

Indexed keywords

GLYCOPROTEIN; LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINIA VIRUS; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; DEFECTIVE VIRUSES; HN PROTEIN; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0032843743     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00257-1     Document Type: Article

References (33)

1. Collins P.L., McIntosh K., Chanock R.M. Respiratory synctial virus. Fields B.N., Knipe D.M., Howley P. Fields virology. 1:1996;1313-1351 Lippincott-Reven, Philadelphia. 3 ed.
2. Elango N., Prince G.A., Murphy B.R., Venkatesan S., Chanock R.M., Moss B. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc. Natl. Acad. Sci. USA. 83:1986;1906-1911.
3. Olmsted R.A., Elango N., Prince G.A., Murphy B.R., Johnson P.R., Moss B., Chanock R.M., Collins P.L. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. USA. 83:1986;7462-7466.
4. Wertz G.W., Stott E.J., Young K.K.-Y., Anderson K., Ball L.A. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J. Virol. 61:1987;293-301.
5. Stott E.J., Ball L.A., Young K.K.-Y., Furze J., Wertz G.W. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live virus challenge. J. Virol. 60:1986;607-613.
6. Olmsted R.A., Buller R.M.L., Collins P.L., London W.T., Beeler J.A., Prince G.A., Chanock R.M., Murphy B.R. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Vaccine. 6:1988;519-524.
7. Crowe J.E. Jr, Collins P.L., London W.T., Chanock R.M., Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 11:1993;1395-1404.
8. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66:1992;1277-1281.
9. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 8:1990;497-502.
10. Connors M., Collins P.L., Firestone C.Y., Murphy B.R. Respiratory syncytial virus (RSV) F-protein G-protein, M2-protein (22K), and N-proteins each induce resistance to RSV challenge, but resistance induced by M2-proteins and N-proteins Is relatively short-lived. J. Virol. 65:1991;1634-1637.
11. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA. 93:1996;11341-11348.
12. Paoletti E. Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA. 93:1996;11349-11353.
13. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-stammes MVA. Infection. 3:1975;6-14.
14. Mayr A., Stickl H., Müller H.K., Danner K., Singer H. Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwächten Organismus. Zbl. Bakt. Hyg. 167:1978;375-390.
15. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1991;1031-1038.
16. Carroll M., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 238:1997;198-211.
17. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:1998;347-352.
18. Wyatt L.S., Carroll M.W., Czerny C.-P., Merchlinsky M., Sisler J.R., Moss B. Marker rescue of the host range restricted defects of modified vaccinia virus Ankara. Virology. 251:1998;334-342.
19. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 89:1992;10847-10851.
20. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1040.
21. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 14:1996;1451-1458.
22. Bender B.S., Rowe C.A., Taylor F., Wyatt L.S., Moss B., Small P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70:1996;6418-6424.
23. Durbin A., Wyatt L.S., Slew J., Moss B., Murphy B.R. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine. 16:1998;1324-1330.
24. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak M. Jr, Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
25. Belyakov I.M., Wyatt L.S., Ahlers J.D., Earl P., Pendleton D., Kelsall B.L., Strober W., Moss B., Berzofsky J.A. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:1998;8264-8272.
26. Seth A., Ourmanov I., Kuroda M.J., Schmitz J.E., Carroll M.W., Wyatt L.S., Moss B., Forman M.A., Hirsch V.M., Letvin N.L. Recombinant MVA-SIV gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by an MHC class I/peptide tetramer. Proc. Natl. Acad. Sci. USA. 95:1998;10112-10116.
27. Carroll M.W., Overwiijk W.W., Chamberlain R.S., Rosenberg S.A., Moss B., Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 15:1997;387-394.
28. Nam J.-H., Wyatt L.S., Chae S.-L., Cho H.-W., Park Y.-K., Moss B. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated strain of vaccinia virus expressing JEV prM and E genes. Vaccine. 17:1998;261-268.
29. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1998;1159-1167.
30. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 244:1998;365-396.
31. Whitehead S.S., Firestone C.Y., Collins P.L., Murphy B.R. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology. 247:1998;232-239.
32. Crowe J.E. Jr, Bui P.T., Davis A.R., Chanock R.M., Murphy B.R. A further attenuated derivative of a cold-passaged temperature- sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994;783-790.
33. Murphy B.R., Graham B.S., Prince G.A., Walsh E.E., Chanock R.M., Karzon D.T., Wright P.F. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J. Clin. Microbiol. 23:1986;1009-1014.